EP Patent

EP3695839A4 — THERAPEUTIC AGENT FOR SOLID CANCERS, WHICH CONTAINS AN AXL INHIBITOR AS AN ACTIVE SUBSTANCE

Assigned to Ono Pharmaceutical Co Ltd · Expires 2021-07-14 · 5y expired

What this patent protects

Patent listed against gilteritinib-fumarate.

Drugs covered by this patent

gilteritinib-fumarate (GILTERITINIB FUMARATE)

Patent Metadata

Patent number: EP3695839A4
Jurisdiction: EP
Classification: —
Expires: 2021-07-14
Drug substance claim: No
Drug product claim: No
Assignee: Ono Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.